Kymera Therapeutics to Participate in Upcoming March Investor Conferences
28 Febrero 2024 - 6:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing a new class of small molecule
medicines using targeted protein degradation (TPD), today announced
that the Company will participate in fireside chats at the
following upcoming investor events:
- TD Cowen 44th Annual Healthcare Conference in Boston, MA on
March 6 at 12:50 p.m. ET;
- Leerink Partners Global Biopharma Conference in Miami, FL on
March 12 at 3:40 p.m. ET;
- Jefferies Biotech on the Bay Summit in Miami, FL on March 13,
the Company will host one-on-one meetings only; and
- H.C. Wainwright 2nd Annual Autoimmune & Inflammatory
Disease Virtual Conference on March 28 at 10:30 a.m. ET.
Live webcasts of the presentations will be available under “News
and Events” in the Investors section of the Company’s website at
www.kymeratx.com. A replay of the webcasts will be archived and
available following the events.
About Kymera TherapeuticsKymera is a
clinical-stage biotechnology company pioneering the field of
targeted protein degradation (TPD) to develop medicines that
address critical health problems and have the potential to
dramatically improve patients’ lives. Kymera is deploying TPD to
address disease targets and pathways inaccessible with conventional
therapeutics. Having advanced the first degrader into the clinic
for immunological diseases, Kymera is focused on delivering oral
small molecule degraders to provide a new generation of convenient,
highly effective therapies for patients with these conditions.
Kymera is also progressing degrader oncology programs that target
undrugged or poorly drugged proteins to create new ways to fight
cancer. Founded in 2016, Kymera has been recognized as one of
Boston’s top workplaces for the past several years. For more
information about our science, pipeline and people, please visit
www.kymeratx.com or follow us on X (previously Twitter) or
LinkedIn.
Investor & Media Contact:
Justine KoenigsbergVice President, Investor
Relationsinvestors@kymeratx.com857-285-5300
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024